Literature DB >> 25854650

Update on therapy for narcolepsy.

Michael J Thorpy1.   

Abstract

OPINION STATEMENT: Narcolepsy is a severe, incurable, neurological disorder that is treated by pharmacological management of its symptoms. The main symptoms are excessive daytime sleepiness (EDS) and cataplexy, although addition symptoms that may require treatment include sleep paralysis, hypnagogic hallucinations, and disturbed nocturnal sleep. Sodium oxybate and modafinil/armodafinil are the first-line treatments for EDS, and sodium oxybate for cataplexy. Sodium oxybate treats all the symptoms of narcolepsy, whereas modafinil is effective for EDS only. Alternative medications for EDS include methylphenidate or amphetamines such as dextroamphetamine, lisdexamfetamine, methamphetamine, or combination amphetamine salts. Non-FDA approved medications for cataplexy include norepinephrine reuptake inhibitors such as venlafaxine or atomoxetine. Combination therapy can be more effective for sleepiness such as sodium oxybate and modafinil/armodafinil. Medication for narcolepsy is generally well tolerated and usually required life-long although does not eliminate all symptoms of narcolepsy.

Entities:  

Year:  2015        PMID: 25854650     DOI: 10.1007/s11940-015-0347-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  47 in total

Review 1.  Disrupted nighttime sleep in narcolepsy.

Authors:  Thomas Roth; Yves Dauvilliers; Emmanuel Mignot; Jacques Montplaisir; Josh Paul; Todd Swick; Phyllis Zee
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

2.  The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.

Authors:  Sara Lena Weinhold; Mareen Seeck-Hirschner; Alexander Nowak; Manfred Hallschmid; Robert Göder; Paul Christian Baier
Journal:  Behav Brain Res       Date:  2014-01-07       Impact factor: 3.332

3.  Delusional confusion of dreaming and reality in narcolepsy.

Authors:  Erin Wamsley; Claire E H M Donjacour; Thomas E Scammell; Gert Jan Lammers; Robert Stickgold
Journal:  Sleep       Date:  2014-02-01       Impact factor: 5.849

4.  Drug-induced restless legs syndrome.

Authors: 
Journal:  Prescrire Int       Date:  2010-08

5.  The association between narcolepsy and REM behavior disorder (RBD).

Authors:  S Nightingale; J C Orgill; I O Ebrahim; S F de Lacy; S Agrawal; A J Williams
Journal:  Sleep Med       Date:  2005-05       Impact factor: 3.492

6.  Clinical aspects of narcolepsy-cataplexy across ethnic groups.

Authors:  Michele L Okun; Ling Lin; Zerrin Pelin; Sungchul Hong; Emmanuel Mignot
Journal:  Sleep       Date:  2002-02-01       Impact factor: 5.849

7.  Fluoxetine suppresses human cataplexy: a pilot study.

Authors:  J Frey; C Darbonne
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

8.  Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.

Authors:  Yves Dauvilliers; Claudio Bassetti; Gert Jan Lammers; Isabelle Arnulf; Geert Mayer; Andrea Rodenbeck; Philippe Lehert; Claire-Li Ding; Jeanne-Marie Lecomte; Jean-Charles Schwartz
Journal:  Lancet Neurol       Date:  2013-10-07       Impact factor: 44.182

9.  ImmunoChip study implicates antigen presentation to T cells in narcolepsy.

Authors:  Juliette Faraco; Ling Lin; Birgitte Rahbek Kornum; Eimear E Kenny; Gosia Trynka; Mali Einen; Tom J Rico; Peter Lichtner; Yves Dauvilliers; Isabelle Arnulf; Michel Lecendreux; Sirous Javidi; Peter Geisler; Geert Mayer; Fabio Pizza; Francesca Poli; Giuseppe Plazzi; Sebastiaan Overeem; Gert Jan Lammers; David Kemlink; Karel Sonka; Sona Nevsimalova; Guy Rouleau; Alex Desautels; Jacques Montplaisir; Birgit Frauscher; Laura Ehrmann; Birgit Högl; Poul Jennum; Patrice Bourgin; Rosa Peraita-Adrados; Alex Iranzo; Claudio Bassetti; Wei-Min Chen; Patrick Concannon; Susan D Thompson; Vincent Damotte; Bertrand Fontaine; Maxime Breban; Christian Gieger; Norman Klopp; Panos Deloukas; Cisca Wijmenga; Joachim Hallmayer; Suna Onengut-Gumuscu; Stephen S Rich; Juliane Winkelmann; Emmanuel Mignot
Journal:  PLoS Genet       Date:  2013-02-14       Impact factor: 5.917

10.  Role of orexin in modulating arousal, feeding, and motivation.

Authors:  Natsuko Tsujino; Takeshi Sakurai
Journal:  Front Behav Neurosci       Date:  2013-04-18       Impact factor: 3.558

View more
  7 in total

1.  Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.

Authors:  Mahesh K Kaushik; Kosuke Aritake; Aya Imanishi; Takashi Kanbayashi; Tadashi Ichikawa; Tetsuo Shimizu; Yoshihiro Urade; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-21       Impact factor: 11.205

2.  Disordered Consciousness or Disordered Wakefulness? The Importance of Prolonged Polysomnography for the Diagnosis, Drug Therapy, and Rehabilitation of an Unresponsive Patient With Brain Injury.

Authors:  Francesca Formica; Marco Pozzi; Paolo Avantaggiato; Erika Molteni; Filippo Arrigoni; Flavio Giordano; Emilio Clementi; Sandra Strazzer
Journal:  J Clin Sleep Med       Date:  2017-12-15       Impact factor: 4.062

3.  Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States.

Authors:  Kathleen F Villa; Nancy L Reaven; Susan E Funk; Karen McGaughey; Jed Black
Journal:  Am Health Drug Benefits       Date:  2018-05

4.  Reproducibility of quantitative real-time PCR assay in microRNA expression profiling and comparison with microarray analysis in narcolepsy.

Authors:  Zhenhua Liu; Liling Yang; Yingzi Zhao; Minglu Tang; Fumin Wang; Xiaoting Wang; Guanzhen Li; Yifeng Du
Journal:  Springerplus       Date:  2015-12-24

5.  An Unusual Case of Type 1 Narcolepsy in an Ethiopian Patient.

Authors:  Asefa Mekonnen; Gregory Stimac
Journal:  Ethiop J Health Sci       Date:  2021-01

6.  Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.

Authors:  Y K Lyauk; C Stage; T K Bergmann; L Ferrero-Milliani; D Bjerre; R Thomsen; K P Dalhoff; H B Rasmussen; G Jürgens
Journal:  Clin Transl Sci       Date:  2016-10-18       Impact factor: 4.689

7.  Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Szilvia Vas; Jackie M Casey; Will T Schneider; Lajos Kalmar; A Jennifer Morton
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.